Cline said: “The environmental impact of medical equipment, particularly single-use devices and personal protective equipment, has been highlighted during the pandemic. However, even before the Covid-19 outbreak, medical devices have had a significant environmental impact. Inhalers, for example, contribute around 3% of total NHS greenhouse gas emissions. Many medtech companies have their own individual codes and sustainability strategies, but there is still a role for policy makers to adopt a framework to address the sustainability and environmental challenges in the healthcare sector more broadly.”
The government’s consultation response also confirmed that it would extend the scope of existing regulations to capture certain non-medical products with similar risk profiles, such as dermal fillers and coloured contact lenses. It will also strengthen the powers of the Medicines and Healthcare Products Regulatory Agency (MHRA) over the performance and safety of the highest-risk medical devices.
Ministers will also ensure that products which already have either the UKCA or CE conformity markings can remain on the market after the new regulations come into force, for a period of between three and five years depending on the device. The government will avoid duplication and minimise burdens on the industry by using Medical Device Single Audit Program (MDSAP) certificates to provide a tailored pathway to market approval for medical devices that have received regulatory approval from elsewhere.
Later this year, ministers will publish new regulations and guidance using powers in the 2021 Medicines and Medical Devices Act. The proposed changes are scheduled to come into effect in 2023 alongside a number of transition arrangements to ensure the industry has time to adapt.